Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy

The latest in neo-adjuvant therapy for luminal breast cancer

Exploring extended adjuvant chemotherapy for luminal cancers

Is chemotherapy only a treatment of last resort in luminal breast cancers?

Adjuvant chemotherapy for breast cancer: who needs it?

Chemotherapy in patients with luminal breast cancer and an intermediate risk recurrence score

Kathy S. Albain: Patients with luminal A and B / HER2 negative breast cancer

Highlights on omitting radiotherapy after surgery for luminal A Breast Cancer: The LUMINA Trial

Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic Signatures

Preoperative management of operable cT3 cN1 luminal breast cancer: Upfront neoadjuvant chemotherapy

Optimizing adjuvant treatment in HR+/HER2- early breast cancer

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Neoadjuvant hormonal treatment for luminal breast cancer: rationale, evidence and outcome

Adjuvant Therapy for Breast Cancer

Luminal A vs. Luminal B Breast Cancer: Key Differences

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

The role of immunotherapy in endocrine-refractory luminal breast cancer

Adjuvant Therapy of Breast Cancer